LIBERTAS

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 39 of the 50 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Jun 15, 2023 → Nov 1, 2026

Cited window

Jun 24, 2023 → Nov 1, 2026

Retrieved

Nov 3, 2026

Title

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Registry

NCT05884398

Study IDs

CR109327 · 56021927PCR3020 (Janssen Research & Development, LLC) · 2022-502686-24-00 (EUCT number)

Sponsor

Janssen Research & Development, LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

420 actual

Registered

2023-06-01

Start

2023-08-31 actual

Primary completion

2026-10-12 estimated

Primary endpoint

Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Not yet captured in this edition: a view on manufacturer-attributed guidance for managing apalutamide-associated rash with antihistamines and topical corticosteroids.
• –Not yet captured in this edition: a view on genetic testing and treatment selection for aggressive management of high-volume metastatic castration-sensitive prostate cancer.
• –Not yet captured in this edition: a view on counseling, assessment, dose reduction and discontinuation for apalutamide-associated rash.
• –Not yet captured in this edition: a view on apalutamide rash management and treatment discontinuation in metastatic castration-sensitive prostate cancer.
• –Not yet captured in this edition: a question about stopping ADT after response to apalutamide plus ADT while preserving disease control and reducing side effects.
• –Not yet captured in this edition: a view on treatment de-escalation and quality of life in responding metastatic hormone-sensitive prostate cancer.
• –Not yet captured in this edition: a view on genetic testing and initial treatment selection in synchronous high-volume metastatic castration-sensitive prostate cancer.
• –Not yet captured in this edition: a view on rash counseling, treatment interruption, assessment, dose reduction, discontinuation and severity grading during apalutamide treatment.
• –Not yet captured in this edition: a view on relapse timing as a guide to selecting patients for metastasis-directed therapy.
• –Not yet captured in this edition: a view on grouping nearby metastatic nodes when selecting local treatment to enable time off ADT.
• –Not yet captured in this edition: a view on manufacturer guidance for antihistamines and topical corticosteroids to manage apalutamide-associated rash.
• –Not yet captured in this edition: a view on potentially short-lived treatment sensitivity when weighing treatment intensity in metastatic hormone-sensitive prostate cancer.
• –Not yet captured in this edition: a view on androgen-receptor pathway intensification versus ADT monotherapy in metastatic castration-sensitive prostate cancer.
• –136 passages in 60 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –650 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 37 sources about other trials or topics are not included.
• –Repeated posts, reposts and copies of recordings do not establish additional independent endorsements. Where copies assign the same words to different people, the report keeps those words unnamed and does not count them as separate agreement.
• –No full protocol or exact-trial results publication was available. Spoken descriptions of treatment allocation sometimes differ, and early PSA or symptom observations do not establish the randomized effects of intermittent versus continued ADT.
• –Historical intermittent-ADT studies, EMBARK, ADREAM and other response-guided studies involve different settings, treatment components or stopping rules. Their findings remain attributed supporting arguments, not LIBERTAS results.
• –Clinical anecdotes, reported conference votes and hypothetical patient examples do not establish comparative efficacy, safety or the frequency of a practice. Some testosterone-replacement anecdotes do not specify the patient's disease stage.
• –Trial involvement and company relationships are described as the sources describe them. Those perspectives are not presented as independent validation, and research identity does not add evidentiary weight.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Reimbursement interpretations, affordability mechanisms and practice descriptions are local and time-specific. They are not confirmation of current coverage rules, and statements made at different times do not by themselves establish a change of mind.
• –Parts of the funding discussion and some practical treatment questions were not fully assessed, so the range of arguments supporting or challenging those views may be understated.

How reports are built and checked: Methods.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes how the published edition states something, such as a count, a name or a sentence, without making a new edition, so the version stays the same. Every correction is listed here with its date. Last checked for new commentary Nov 3, 2026 UTC. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "LIBERTAS" (NCT05884398), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "libertas-nct05884398". If you cannot make requests, read https://www.erudio.com/reports/libertas-nct05884398.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05884398", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05884398 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/libertas-nct05884398.json
curl https://www.erudio.com/reports/libertas-nct05884398.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "libertas-nct05884398" })